Precipio Earnings Call Signals Profitable Growth Pivot

Precipio ((PRPO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Precipio’s latest earnings call painted a cautiously optimistic picture, as management highlighted a move to positive cash flow, 30% revenue growth to $24M, and better gross margins alongside a cleaner balance sheet. Executives also acknowledged uneven performance in the Products division and execution risks, but outlined concrete fixes and a clear strategy aimed at accelerating growth into 2026.

Revenue Growth and Scale

Precipio reported fiscal 2025 revenue of $24.0M, up 30% year over year, underscoring solid demand momentum despite pockets of volatility. Growth was led by Pathology Services, where increased demand for specialized diagnostic and molecular testing continued to pull in higher case volumes from both new and existing customers.

Positive Cash Flow and Balance Sheet Cleanup

Management emphasized reaching a strategic inflection point as the company turned positive on cash flow during 2025, easing prior funding concerns. The repayment of the Change Healthcare loan and the exercise of remaining financial warrants simplified the capital structure, giving the company more flexibility to reinvest in growth.

Gross Margin Improvement

Consolidated gross margin improved from 41% in 2024 to 45% in 2025, reflecting better economics as volume scaled. Executives attributed this 4‑point gain primarily to higher case volumes, a more favorable case mix, and operational efficiencies within Pathology Services that reduced unit costs.

Pathology Services: Organic Growth and Leverage

Pathology Services continued to be the growth engine, benefiting from both new customer wins and increased testing from existing accounts. With laboratory infrastructure still operating below capacity, management noted that each additional case drops through at higher incremental margin, strengthening both profitability and cash generation.

Products Manufacturing Scalability

The Products division showcased its manufacturing scalability in Q4, posting an eye‑catching product gross margin of 90% versus about 30% in Q3 and a historical 40–50% range. This spike came from a concentrated production run to prebuild inventory for expected Q1 downtime, illustrating that higher volume can support a much more attractive margin profile.

Commercial Team Strengthened

Recognizing that sales coverage had been a bottleneck, Precipio significantly upgraded its commercial team in January 2026 with the hiring of a seasoned Chief Commercial Officer and two experienced business development professionals. This marks a step up from a largely part‑time, under‑resourced effort and is intended to accelerate adoption of the company’s products.

Clinical Validation and Thought Leadership

Management spotlighted new clinical and academic validation as a key competitive asset, including a joint study with Memorial Sloan Kettering supporting the Bloodhound BCR‑ABL platform. A poster presentation with Wayne State University on the HemeScreen panel further reinforced Precipio’s presence in the molecular diagnostics community and bolstered its scientific credibility.

Market Engagement and Share Price Momentum

The company reported more than 50 investor interactions during 2025 and pointed to roughly 300% share‑price appreciation over the year as a sign of growing market confidence. Management framed this performance as a byproduct of both improved fundamentals and increased outreach to the investment community.

Strategic Product-Service Opportunities

A centerpiece of the call was a plan to launch a next‑day rapid molecular AML testing service that blends the strengths of Products and Pathology Services. Targeting an estimated $500M U.S. market, the offering aims to deliver next‑day results with a comprehensive five‑day follow‑up report, shortening turnaround times for a critical oncology indication.

Products Revenue Underperformance

Despite strategic promise, the Products division fell short of revenue expectations in 2025 as operational pauses and customer‑side disruptions offset new business wins. Machine downtime, staffing gaps, and onboarding delays at key labs muted the topline contribution from products relative to management’s initial plans.

Earlier Commercial Resource Constraints

Management was candid that the Products business operated for much of 2025 with an undersized commercial footprint, relying on one senior executive part‑time plus a junior sales representative. This lean structure limited customer acquisition and slowed pipeline conversion, a gap the January 2026 hiring spree is designed to close.

Product Margin Volatility and One-Time Effects

Product margins were highly volatile, swinging from roughly 30% in Q3 to 90% in Q4 as the company invested in expanded facilities and then executed a concentrated production run. Executives stressed that the fourth‑quarter margin is not a new baseline but rather a demonstration of potential profitability should volume remain consistently elevated.

Customer Onboarding and Sales Cycle Delays

The call underscored that diagnostic industry adoption timelines can be slow, with customers needing to validate assays and adjust workflows, IT systems, and regulatory processes before going live. These multi‑step onboarding requirements delayed revenue recognition and contributed to the slower‑than‑expected ramp in product revenues.

Operational Dependence and Revenue Fluctuation Risk

Precipio’s revenue remains partly exposed to operational interruptions at customer labs, including equipment downtime and staffing shortages that can temporarily halt testing. Management highlighted a strategy to act as a backup lab for clients to mitigate some of this dependence, but acknowledged that these factors created noticeable revenue variability in 2025.

Planned Manufacturing Downtime and Inventory Timing

The company prebuilt product inventory in Q4 to cover an anticipated two‑to‑four‑week equipment downtime in Q1 2026, which drove the one‑time margin distortion. While the move protected near‑term customer supply, it also emphasized how production scheduling and transitions can temporarily skew financial metrics and must be managed carefully.

Forward-Looking Guidance and Strategic Mix Shift

Looking ahead, management plans to reinvest cash from the higher‑margin pathology business into scaling the Products segment, pursuing a sizable U.S. opportunity. Over the next three to five years, the goal is to transition from a roughly 90/10 services‑to‑products revenue mix toward a more balanced portfolio while building on the new commercial hires and the AML testing launch.

Precipio’s earnings call portrayed a company turning an important financial corner while still wrestling with the growing pains of scaling a products business. For investors, the key watch points will be execution on the expanded commercial strategy, stabilization of product margins, and progress toward a more diversified revenue mix without sacrificing the momentum in Pathology Services.